◀ Back to CD79B
CD79B — VEGFA
Text-mined interactions from Literome
Mayerhofer et al., Blood 2002
:
BCR/ABL induces expression of
vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin ... We show here that the CML associated oncogene
BCR/ABL induces
VEGF gene expression in growth factor dependent Ba/F3 cells ...
BCR/ABL induced
VEGF gene expression was counteracted by the phosphoinositide 3-kinase ( PI3-kinase ) inhibitor LY294002 and rapamycin, an antagonist of mammalian target of rapamycin (mTOR), but not by inhibition of the mitogen activated protein kinase pathway
Ebos et al., Mol Cancer Res 2002
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive...) :
Imatinib mesylate ( STI-571 ) reduces
Bcr-Abl mediated
vascular endothelial growth factor secretion in chronic myelogenous leukemia ... Transfection of
BCR-ABL into murine myeloid 32D and human megakaryocyte MO7e hematopoietic cells
resulted in enhanced
VEGF expression, which could be further elevated by the exposure to cytokines such as interleukin 3 and granulocyte macrophage colony stimulating factor
Li et al., J Int Med Res 2009
(Leukemia, Myelogenous, Chronic, BCR-ABL Positive) :
Studies have shown that
vascular endothelial growth factor ( VEGF ), a major and potent inducer of angiogenesis, is directly
triggered by the disease related oncogene
Bcr-Abl in Bcr-Abl positive cells